Eli Lilly, dropping $150M
upfront for a drug that regulates T-Reg activity. Lots of potential here - if, like me, you believe Androgenetic Alopecia is an autoimmune disease, then this new drug should give you some hope for a new type of treatments altogether. Eli Lilly is valued at $86B and generates revenues of $22B / yr. It is the 243rd largest public company in the world. If this type of drug can have any impact on hairloss, we should all be super excited that Eli Lilly saw enough potential to drop $150M on helping to get it to market.
http://www.fiercebiotech.com/biotec...to-phase-1-drug-broad-immune-and-inflammatory
"The data suggest NKTR-358 preferentially increases the number and activity of Tregs
without having a significant effect on non-Tregs. And that it suppresses antigen-driven inflammation in mice and primates.
This is significant for patients with autoimmune diseases as these conditions are associated with depleted numbers or activity of Tregs. The lack of effective Tregs means immune regulation is weakened, leading to autoimmunity."
Now this article does not claim that NKTR-358 would be effective or even designed for hairloss treatment, but the reason i'm personally excited is that recent studies linked T-Reg dysfunction to hairloss (see here:
https://www.ucsf.edu/news/2017/05/407121/new-hair-growth-mechanism-discovered). The article does claim that NKTR-358 "may treat an array of immune disorders by fixing the underlying regulatory dysfunction"
This thing is not even in phase 1 testing, but i am f*****g excited about it. Who's with me?